Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS
Gutzmer R, Schulze HJ, Hauschild A, Leiter U, Meier F, Haferkamp S, Ulrich C, Wahl RU, Berking C, Herbst R, Haeckl M, Schadendorf D (2021)
Publication Type: Journal article
Publication year: 2021
Journal
DOI: 10.1111/jdv.17332
Abstract
Background Basal cell carcinoma (BCC) can arise by the uncontrolled proliferation of cells from multiple epidermal compartments due to aberrant activation of the Hedgehog (Hh) signalling pathway. Vismodegib, a small-molecule inhibitor of this pathway, is approved for treatment of patients with locally advanced (la) BCC inappropriate for surgery or radiotherapy or patients with symptomatic metastatic (m) BCC.
Authors with CRIS profile
Involved external institutions
Mühlenkreiskliniken
Germany (DE)
Fachklinik Hornheide
Germany (DE)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Universitätsklinikum Tübingen
Germany (DE)
Universitätsklinikum Carl Gustav Carus Dresden
Germany (DE)
Universitätsklinikum Regensburg
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen
Germany (DE)
Helios Klinikum Erfurt
Germany (DE)
Roche Deutschland Holding GmbH
Germany (DE)
Universitätsklinikum Essen
Germany (DE)
Germany (DE)
Fachklinik Hornheide
Germany (DE)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Universitätsklinikum Tübingen
Germany (DE)
Universitätsklinikum Carl Gustav Carus Dresden
Germany (DE)
Universitätsklinikum Regensburg
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen
Germany (DE)
Helios Klinikum Erfurt
Germany (DE)
Roche Deutschland Holding GmbH
Germany (DE)
Universitätsklinikum Essen
Germany (DE)
How to cite
APA:
Gutzmer, R., Schulze, H.-J., Hauschild, A., Leiter, U., Meier, F., Haferkamp, S.,... Schadendorf, D. (2021). Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.17332
MLA:
Gutzmer, R., et al. "Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS." Journal of the European Academy of Dermatology and Venereology (2021).
BibTeX: Download